secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2021-08-23T23:59:59+00:00
Accession:  0001193125-21-254149
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio appoints Fred Hassan, Andrea Ellis, and Douglas Dachille to board of directors
--------------------------------------------------------------------------------

- Board expanded from 11 to 14 members; three new independent directors effective August 17, 2021.
- Fred Hassan, former Schering-Plough CEO and Warburg Pincus director, appointed as Class II director.
- Andrea Ellis, CFO of Lime and former Goldman Sachs banker, appointed as Class II director and audit committee member.
- Douglas Dachille, former AIG CIO, appointed as Class III director; previously served as board observer.
- Each director granted option to purchase $1.2M of common stock at $49.54, vesting over three years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000119312521254149/0001193125-21-254149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000119312521254149/d219643d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-254149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer